Financial Ratios

KOBO BIOTECH LTD.

NSE : NABSE : 531541ISIN CODE : INE881A01015Industry : Pharmaceuticals & DrugsHouse : Private
BSE4.100 (0 %)
PREV CLOSE ( ) 4.10
OPEN PRICE ( ) 4.47
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10916
TODAY'S LOW / HIGH ( )4.08 4.47
52 WK LOW / HIGH ( ) 2.046.01
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-2.33-6.39-8.07-8.82-10.27
   CEPS(Rs)-0.62-4.46-5.71-6.35-7.69
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-53.72-51.39-45.00-36.92-28.11
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)
   EBIT Margin(%)
   Pre Tax Margin(%)
   PAT Margin (%)
   Cash Profit Margin (%)
Performance Ratios
   ROA(%)-7.19-9.83-8.24-8.83-10.08
   ROE(%)0.000.000.000.000.00
   ROCE(%)-36.84-17.59-5.31-3.93-5.74
   Asset Turnover(x)0.000.000.000.000.00
   Sales/Fixed Asset(x)0.000.000.000.000.00
   Working Capital/Sales(x)0.000.000.000.000.00
Efficiency Ratios
   Fixed Capital/Sales(x)
   Receivable days
   Inventory Days
   Payable days
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-3.06-1.23-1.30-0.46-0.60
   Price/Book(x)-0.04-0.11-0.16-0.08-0.16
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)
   EV/Core EBITDA(x)-97.37-14.66-100.45-394.17-146.66
   EV/EBIT(x)-25.97-10.18-32.97-39.43-24.68
   EV/CE(x)1.911.941.201.091.03
   M Cap / Sales
Growth Ratio
   Net Sales Growth(%)
   Core EBITDA Growth(%)85.87-280.78-321.4761.2443.46
   EBIT Growth(%)63.20-79.86-28.4634.79-6.25
   PAT Growth(%)63.5320.838.4514.12-2.24
   EPS Growth(%)63.5320.838.4514.12-2.24
Financial Stability Ratios
   Total Debt/Equity(x)-1.09-1.15-2.43-2.85-3.53
   Current Ratio(x)0.230.230.530.560.59
   Quick Ratio(x)0.120.120.350.370.39
   Interest Cover(x)0.00-111.95-0.77-0.45-0.69
   Total Debt/Mcap(x)30.8910.7414.7836.4221.57

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.